NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Instruments & Supplies · USD

AtriCure, Inc. (ATRC) Stock Analysis

AtriCure, Inc. (ATRC) is a Medical Instruments & Supplies stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ATRC

$57.67

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ATRC with… →

ATRC Key Statistics

As of Oct 21, 2026
Trading
Open
$57.73
Previous Close
$57.67
Day's Range
57.13–59.29
52-Week Range
25.36–61.70
Volume
566.27K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.25
Valuation
Market Cap
$2.93B
P/E Ratio
274.62
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
132.89
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
10.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.15
EPS (ttm)Profit attributable to each share over the last twelve months.
0.21
Financials (FY)
Revenue (FY)
$534.53M+14.88%
Net Income (FY)
−$11.45M
Profit marginThe share of revenue left as profit after all costs and taxes.
1.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
50.87M
1-Year Return
+55.86%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.07M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ATRC closed at $57.67, +55.86% over 1 year.

AtriCure, Inc. (ATRC) has a market capitalization of $2.93B.

In fiscal 2025, ATRC reported revenue of $534.53M.

ATRC Stock Return by Calendar Year

AtriCure, Inc. (ATRC) 10-year return: what $10,000 became

1 year
$10,000 $15,586
+55.86%
5 years
$10,000 $7,975
−20.25%
10 years
$10,000 $32,992
+229.92%

If you had invested $10,000 in AtriCure, Inc. (ATRC) 10 years ago, at the close on October 21, 2016, it would have been worth $32,992 at the close on October 21, 2026: +229.92% in total, +12.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+45.78%
2025+29.45%
2024−14.37%
2023−19.58%
2022−36.17%
2021+24.90%
2020+71.24%
2019+6.24%
2018+67.76%
2017−6.80%
2016 (partial year)+39.29%

As of October 21, 2026.

ATRC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$534.53M−$11.45M−2.1%
2024$465.31M−$44.70M−9.6%
2023$399.25M−$30.44M−7.6%
2022$330.38M−$46.47M−14.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$534.53M$400.78M−$9.45M−$11.45M−2.1%
2024$465.31M$347.52M−$40.01M−$44.70M−9.6%
2023$399.25M$300.37M−$26.68M−$30.44M−7.6%
2022$330.38M$245.94M−$42.67M−$46.47M−14.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ATRC Valuation vs Medical Instruments & Supplies Median

Median of 50 stocks
MetricATRCMedical Instruments & Supplies medianvs median
P/E274.6231.198.8x the median
P/S ratio5.152.6098% above
Profit margin1.85%1.62%0.2 pts above

Medians across 50 Medical Instruments & Supplies stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AtriCure, Inc. (ATRC) at $2.93B. The company sits in the Healthcare sector, in the Medical Instruments & Supplies industry. Headcount on file is 1,350.

ATRC last closed at $57.67 on October 21, 2026. The close was unchanged from the previous session. Over the past 52 weeks the price has ranged from $25.36 to $61.70. The latest close sits 127.41% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $534.53M. Against the prior fiscal year total of $465.31M, that is a change of +14.88%. The same year closed with a net loss of $11.45M. The reported profit margin is 1.85%. That is 0.2 percentage points above the Medical Instruments & Supplies median of 1.62%. Trailing earnings per share are 0.21.

Across the 4 fiscal years on file, revenue moves from $330.38M in 2022 to $534.53M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 274.62. That is 8.8 times the Medical Instruments & Supplies median of 31.19. The forward P/E on file is 132.89. The PEG ratio, which sets the P/E against expected earnings growth, reads 10. Measured against sales, the shares trade at 5.15 times revenue. On price-to-sales that is 98.25% above the Medical Instruments & Supplies median of 2.6. 50 Medical Instruments & Supplies companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.25. Daily returns over the trailing 10 years annualize to a volatility of 43.98%. Over the trailing twelve months the total return is +55.86%. Across 10 years the annualized return works out at +12.68%.

Growth & Income

No dividend is on file for ATRC.

So far in 2026 the total return is +45.78%. The strongest complete calendar year on file is 2020 at +71.24%; the weakest is 2022 at −36.17%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

AtriCure, Inc. (ATRC) operates in the Medical Instruments & Supplies industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AtriCure, Inc. ATRC $2.93B 274.6
Intuitive Surgical, Inc. ISRG $151.25B 51.8
Becton, Dickinson and Company BDX $52.79B 45.1
Medline Inc. MDLN $47.51B 88.3

The Medical Instruments & Supplies industry average P/E ratio is 31.2x. AtriCure, Inc. trades at a P/E of 274.6.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Instruments & Supplies Stocks

ISRG

Intuitive Surgical, Inc.

$151.25B

 BDX

Becton, Dickinson and Company

$52.79B

 MDLN

Medline Inc.

$47.51B

 RMD

ResMed Inc.

$34.63B

 ALC

Alcon Inc.

$32.60B

 WST

West Pharmaceutical Services, Inc.

$27.69B
View all Medical Instruments & Supplies stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AtriCure, Inc.

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Visit website →